StockData
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ) stock

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$240.71+0.94 (+0.39%)

Close on Nov 17, 2026Market cap $15.63BP/E 78.4Yield –

Jazz Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Jazz Pharmaceuticals's price to sales ratio was 3.5× on Nov 11, 2026, against 2.6× a year earlier. Over the last 5 years it ranged from 1.7× to 3.6×, with a median of 2.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.5×+1.0
2025Dec 31, 20252.5×+0.5
2024Dec 31, 20242.0×−0.2
2023Dec 29, 20232.3×−0.5
2022Dec 30, 20222.8×+0.2
2021Dec 31, 20212.6×−1.4
2020Dec 31, 20204.1×−0.2
2019Dec 31, 20194.2×+0.1
2018Dec 31, 20184.1×−1.1
2017Dec 29, 20175.2×+0.5
2016Dec 30, 20164.7×−2.3
2015Dec 31, 20157.0×−2.3
2014Dec 31, 20149.3×−0.2
2013Dec 31, 20139.5×+3.3
2012Dec 31, 20126.2×−0.3
2011Dec 30, 20116.5×+1.9
2010Dec 31, 20104.6×–

More Jazz Pharmaceuticals figures

See a number that looks wrong?